(ANSA) – ROME, JUL 01 – The German CureVac announced that the final results of the trial showed that its coronavirus vaccine has an efficacy rate of just 48%, much lower than that developed by its mRNA rivals BioNTech and Moderna. The company said its vaccine performed slightly better among people between the ages of 18 and 60 compared to the older age groups, with efficacy rising to 53 percent. The company said its process was complicated by the prevalence of numerous variants of the coronavirus. (HANDLE).
REPRODUCTION RESERVED © Copyright ANSA
Get the embed code